Overall, these data suggest that TRK inhibitors are associated with significantly improved PFS in pediatric patients with high-grade gliomas compared to adults (17 ± 10.5 vs. 8.5 ± 3.5 months, p < 0.001). This evidence concerns the gene NTRK1 and central nervous system cancer.